Literature DB >> 11043104

Management of metastatic disease to soft tissue.

T A Damron1, J Heiner.   

Abstract

Metastases to soft tissue are rare clinical problems. Most metastases are caused by carcinomatous deposits in the skeletal muscle, with lung carcinoma being the most common primary cause. Pain is more commonly observed in association with metastatic soft tissue masses than for soft tissue sarcomas. Treatment should be individualized, but for most carcinomas, initial radiotherapy treatment is recommended. Prognosis varies with the underlying disease, but for the typical patient with a metastatic carcinoma, mean survival duration is approximately 6 months.

Entities:  

Mesh:

Year:  2000        PMID: 11043104     DOI: 10.1016/s0030-5898(05)70183-8

Source DB:  PubMed          Journal:  Orthop Clin North Am        ISSN: 0030-5898            Impact factor:   2.472


  5 in total

1.  Orthopaedic case of the month: a 72-year-old man with a painful flexion contracture of the left thigh.

Authors:  Nathan L Cafferky; W James Malone; Thomas R Bowen
Journal:  Clin Orthop Relat Res       Date:  2012-09-08       Impact factor: 4.176

Review 2.  Adductor longus muscle metastasis of transitional cell carcinoma of the urinary bladder.

Authors:  Irfan Koca; Mehmet Ucar; Zehra Bozdag; Samet Alkan
Journal:  BMJ Case Rep       Date:  2014-05-14

Review 3.  [Muscle metastasis of an epidermoid carcinoma of the cervix: report of a case and review of the literature].

Authors:  Imane Mezouri; Hanane Chenna; Sara Bellefqih; Hanan ElKacemi; Tayeb Kebdani; Noureddine Benjaafar
Journal:  Pan Afr Med J       Date:  2014-05-07

4.  PET/CT Findings of a Patient with Striped Muscle Metastasis of Invasive Breast Carcinoma

Authors:  Rabiye Uslu Erdemir; Özlem Elmas
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

5.  Intraneural metastasis of gastric carcinoma leads to sciatic nerve palsy.

Authors:  Jiro Ichikawa; Seiichi Matsumoto; Takashi Shimoji; Taisuke Tanizawa; Tabu Gokita; Keiko Hayakawa; Kaoru Aoki; Saori Ina; Hiroaki Kanda
Journal:  BMC Cancer       Date:  2012-07-25       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.